Arimidex 2 - Stealth Labs

Anastrozole, was developed by Zeneca Pharmaceuticals and officially approved in the United States in 1995. As the first of the third-generation selective oral aromatase inhibitors, it was created to treat hormone-responsive breast cancer in postmenopausal women, offering a potent alternative to tamoxifen. Its approval followed extensive trials, including the landmark ATAC study based in Rome, which demonstrated its superiority over tamoxifen in both disease regression and overall survival rates. This pivotal trial, published in 2002, cemented anastrozole’s place in clinical oncology.

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For detailed information about Arimidex 2 by Stealth Labs, consult with your doctor or healthcare professional.